Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Preferred Stock Liabilities: 2020

  • Janux Therapeutics' Preferred Stock Liabilities was N/A to $21.6 million in Q4 2020 from the same period last year, while for Dec 2020 it was $21.6 million, marking a year-over-year change of. This contributed to the annual value of $21.6 million for FY2020, which is N/A change from last year.
  • According to the latest figures from Q4 2020, Janux Therapeutics' Preferred Stock Liabilities is $21.6 million.
  • In the past 5 years, Janux Therapeutics' Preferred Stock Liabilities registered a high of $21.6 million during Q4 2020, and its lowest value of $21.6 million during Q4 2020.
  • In the last 1 years, Janux Therapeutics' Preferred Stock Liabilities had a median value of $21.6 million in 2020 and averaged $21.6 million.